Vaginal atrophy affects many of your patients

Vaginal atrophy is a common issue

Vaginal atrophy is a significant problem amongst women who have gone through the menopause. About half of all postmenopausal women experience discomfort due to vaginal atrophy.1

Vaginal atrophy is undertreated

50% of postmenopausal women with genitourinary symptoms have never used any therapy for this problem.2

Patients need your help to talk about vaginal atrophy

Women want accurate medical information about vaginal atrophy, but they are more likely to want the HCP to initiate the conversation.3

Vaginal atrophy is a common issue

Vaginal atrophy is a significant problem amongst women who have gone through the menopause. About half of all postmenopausal women experience discomfort due to vaginal atrophy.1

Vaginal atrophy is undertreated

50% of postmenopausal women with genitourinary symptoms have never used any therapy for this problem.2

Patients need your help to talk about vaginal atrophy

Women want accurate medical information about vaginal atrophy, but they are more likely to want the HCP to initiate the conversation.3

Symptoms

Vaginal atrophy has many symptoms which affect every part of her life4.

Vaginal dryness

Dyspareunia

Itching

Dysuria

Burning

Vaginal symptoms impact women in many ways, including:5

  • Well-being
  • Function
  • Quality of Life
  • Sexual function
  • Self-perception
  • Body image

Diagnosis

Women need prompt diagnosis and treatment

When you identify vaginal atrophy, it may favour early management and treatment.6

NICE guidelines suggest local treatment over systemic hormonal replacement therapy.7

They state that vaginal oestrogen should be offered to women to treat the symptoms of vaginal atrophy.7

When choosing a treatment for vaginal atrophy, the dose is important

The British Menopause Society WHC guideline advocates to use the lowest effective HRT dose for treating symptoms.8

Release her confidence from within.

To book a visit from a Consilient Health BlisselⓇ trained healthcare manager, please click here to complete our DATA compliant form:

Contact us

How BlisselⓇ
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel9,10

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com

1.Nappi RE. and Palacios S. Climacteric. 2014;17:3–9. 2. NAMS position statement. Menopause. 2020;27(9):976-92. 3. Krychman M, et al. J Sex Med 2017;14:425-433. 4. Palma F, et al. Maturitas. 2018;108:18–23. 5. Moral E, et al. Menopause. 2018;25(12):1418-23. 6. Cagnacci A, et al. Climacteric. 2019;22(1):85-89. 7. NICE. Menopause: diagnosis and management (NG23). Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed December 2022. 8. British Menopause Society Women’s Health Concern Fact Sheet: HRT Benefits and Risks; Nov 2017. 9. Cano A, et al. Menopause. 2012;19(10):1130-9.
10. BlisselⓇ 50 micrograms/g vaginal gel. Summary of product characteristics.

Date of preparation: July 2025 | UK-BLS-43b(3)

BlisselⓇ (Estriol 50 Micrograms/G Vaginal Gel)
Safety Information:

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1


Date of preparation: April 2026 Item code: UK-BLS-671(1)